HC Wainwright Predicts OmniAb’s Q2 Earnings (NASDAQ:OABI)

OmniAb, Inc. (NASDAQ:OABI) – Equities researchers at HC Wainwright issued their Q2 2026 earnings per share estimates for OmniAb in a report released on Thursday, March 5th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.09) for the quarter. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.08) EPS and FY2030 earnings at $0.00 EPS.

A number of other research analysts also recently issued reports on OABI. Benchmark reiterated a “buy” rating on shares of OmniAb in a research note on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of OmniAb in a report on Monday, December 22nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $6.67.

OmniAb Stock Performance

Shares of OmniAb stock opened at $1.89 on Friday. The business has a 50-day simple moving average of $1.83 and a 200-day simple moving average of $1.75. The company has a market cap of $272.08 million, a PE ratio of -3.32 and a beta of 0.13. OmniAb has a one year low of $1.22 and a one year high of $3.45.

OmniAb (NASDAQ:OABI) last issued its quarterly earnings results on Wednesday, March 4th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The company had revenue of $8.38 million for the quarter, compared to analysts’ expectations of $9.00 million. OmniAb had a negative return on equity of 23.99% and a negative net margin of 347.04%.

Insider Activity at OmniAb

In other news, CFO Kurt A. Gustafson sold 23,922 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $1.96, for a total value of $46,887.12. Following the completion of the transaction, the chief financial officer owned 252,688 shares in the company, valued at approximately $495,268.48. This represents a 8.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Matthew W. Foehr sold 30,843 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.71, for a total transaction of $52,741.53. Following the completion of the transaction, the chief executive officer directly owned 4,403,277 shares in the company, valued at $7,529,603.67. This trade represents a 0.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 130,021 shares of company stock valued at $233,398. 8.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On OmniAb

Several hedge funds and other institutional investors have recently bought and sold shares of OABI. AQR Capital Management LLC purchased a new stake in OmniAb in the first quarter valued at $25,000. Osaic Holdings Inc. grew its holdings in shares of OmniAb by 214.4% during the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock worth $25,000 after purchasing an additional 9,716 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of OmniAb by 92.5% during the third quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock worth $35,000 after purchasing an additional 10,438 shares in the last quarter. Cerity Partners LLC increased its position in shares of OmniAb by 111.5% during the second quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock worth $39,000 after purchasing an additional 11,919 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of OmniAb by 96.6% in the 4th quarter. SG Americas Securities LLC now owns 23,141 shares of the company’s stock valued at $43,000 after purchasing an additional 11,369 shares during the last quarter. 72.08% of the stock is currently owned by institutional investors and hedge funds.

About OmniAb

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.